Lia Kallenberger | Senior Scientist
Araris Biotech AG

Lia Kallenberger, PhD, is a Senior Scientist at Araris Biotech AG in Zurich, Switzerland, where she leads antibody-drug conjugate (ADC) discovery programs spanning target feasibility, drug selection, production, analytics, as well as functional cellular assays and in vivo studies. She has a PhD in Cancer Biology from the University of Zurich and brings over twelve years of experience in molecular and cellular biology, focusing on translating biological insights into differentiated therapeutic candidates. Before joining Araris, she was a Senior Scientist at Adrestia Therapeutics (Cambridge, UK), building human disease models and CRISPR/Cas9 screening approaches to identify targets for the treatment of rare diseases.